Core Insights - The company reported a net sales decline of 7.0% year-on-year for FY 2025, totaling €848.2 million, with a comparable decline of 5.9% when excluding the impact of the Haverhill site divestment [2][9] - EBITDA improved significantly to €9.9 million from a loss of €43.6 million in 2024, while Core EBITDA rose to €66.2 million, reflecting a 31.2% increase from €50.4 million in 2024 [2][20] - The company anticipates a further decrease of around 10% in net sales for 2026 due to portfolio rationalization and challenging market conditions, while aiming to maintain Core EBITDA margins in line with FY 2025 [3][44] Financial Performance - The operating income for FY 2025 was reported at €(130.6) million, compared to €(120.4) million in 2024, with impairments of assets totaling €77.8 million [2][20] - The net income for FY 2025 was €(211.2) million, worsening from €(130.6) million in 2024, with a basic EPS of €(2.23) compared to €(1.38) in the previous year [2][20] - Free cash flow before financing activities reached €51.5 million, a significant increase from €15.0 million in 2024 [26] Operational Developments - The FOCUS-27 transformation plan is on track, with key actions executed to streamline the API portfolio and enhance operational efficiencies [4][28] - The company successfully divested the Haverhill site, contributing to a sustainable reduction in the cost base [6][28] - Cost control measures led to a €10 million decrease in operating expenses, resulting in a Core EBITDA margin increase to 7.8% from 5.5% in 2024 [5][21] Environmental and Social Responsibility - The company achieved a 33% share of renewable energy consumption in FY 2025, up from 26% in 2024, and reduced GHG emissions (scope 1 and 2) to 83,962 metric tons of CO2e [8][34] - The total recordable injury frequency rate was reported at 4.4, slightly above the target of 2.5, indicating a need for continued focus on workplace safety [35][37] Strategic Outlook - The company is focusing on high-margin complex molecules and plans to optimize its supply chain to enhance competitiveness [31][32] - A restructuring cost range of €110 to €120 million is expected, with a maintained CAPEX envelope of €350 to €400 million planned for 2024 to 2027 [32][44] - The company aims to position itself as a reliable European supplier for complex APIs, emphasizing the importance of resilient supply chains in the pharmaceutical industry [33][31]

Core Insights - The company reaffirmed its 2025 Core EBITDA margin guidance of 7% to 9%, aiming for the upper part of the range despite challenging market conditions [1][5][3] - Net Sales for H1 2025 were €412.1 million, reflecting an 8.2% year-on-year decline, primarily due to a €21 million one-off impact in H1 2024 [1][2][6] - EBITDA improved to €5.0 million from a loss of €(1.4) million in H1 2024, while Core EBITDA decreased to €39.5 million with a margin of 9.6% [1][14][16] Financial Performance - H1 2025 Net Sales decreased by 8.2% compared to H1 2024, with a Gross Profit of €76.6 million and a Gross Profit Margin of 18.6% [2][13] - Core EBITDA margin fell from 10.6% in H1 2024 to 9.6% in H1 2025, influenced by various factors including the impact of Buserelin's stock clearance [14][15] - Net Income improved to €(28.5) million from €(34.8) million in H1 2024, with Basic EPS at €(0.30) [2][16] Sales Breakdown - API Solutions' net sales decreased by 9.8% to €299.7 million, while CDMO sales fell by 3.4% to €112.4 million [7][9] - Sales to Sanofi dropped by 24.4% to €123.9 million, while sales to Other Clients increased by 4.3% [11][12] - The decline in Large molecules was significant, down 49.3%, while Biochemistry molecules derived from fermentation saw a 20.7% increase [10][12] Strategic Developments - The company completed the divestment of the Haverhill site, which contributed €14 million in net sales and €3 million in Core EBITDA in H1 2025 [4][24][25] - An agreement with the French government was signed to secure up to €140 million in public aid for the IPCEI Med4Cure project [23] - The FOCUS-27 strategic plan is being executed thoroughly, with a focus on cost control and operational efficiency [1][21][22] Cash Flow and Capital Expenditure - The Net Cash Position at the end of June 2025 was €1.1 million, down from €25.2 million at the end of December 2024 [17][20] - H1 2025 CAPEX reached €(37.8) million, with 60% allocated to growth projects, and full-year CAPEX expected to be between €80 million and €90 million [19][20] - Free Cash Flow before financing activities was €(20.0) million, a decrease from €10 million in H1 2024 [19]